The Journal of Toxicological Sciences, 2002, Vol.27(3), pp.147-163
2002
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- TWENTY-SIX WEEK CARCINOGENICITY STUDY OF AMPICILLIN IN CB6F1-TgrasH2 MICE
- Ist Teil von
- The Journal of Toxicological Sciences, 2002, Vol.27(3), pp.147-163
- Ort / Verlag
- Tokyo: The Japanese Society of Toxicology
- Erscheinungsjahr
- 2002
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- As a part of the ILSI-HESI Alternative to Carcinogenicity Testing (ACT) program, we performed a 26-week carcinogenetic study of nonmutagenic drug, ampicillin (ABPC) in Tg-rasH2 mice. ABPC was given to Tg-rasH2 mice (0, 350, 1000, 3000 mg/kg, p.o.) and Non-Tg mice (0, 3000 mg/kg, p.o.) daily for 26 weeks. As a positive control, a single dose of MNU was administered once to Tg-rasH2 mice (75 mg/kg, i.p.). In this study, Tg-rasH2 mice did not demonstrate any increases in tumor development in response to ABPC. Thus, ABPC had no carcinogenicity in the 26-week carcinogenesis study in Tg-rasH2 mice or in a 2-year carcinogenesis study in B6C3F1 mice.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0388-1350eISSN: 1880-3989DOI: 10.2131/jts.27.147Titel-ID: cdi_proquest_miscellaneous_18040803
- Format
- –
- Schlagworte
- 26-week carcinogenesis study, Administration, Oral, Ampicillin, Ampicillin - administration & dosage, Ampicillin - pharmacokinetics, Ampicillin - toxicity, Animals, Biological and medical sciences, Body Weight - drug effects, Carcinogenicity Tests, Carcinogens - administration & dosage, Carcinogens - pharmacokinetics, Carcinogens - toxicity, Dose-Response Relationship, Drug, Drug toxicity and drugs side effects treatment, Female, Genes, ras, ILSI-HESI ACT, Longevity - drug effects, Male, Medical sciences, Mice, Mice, Inbred Strains, Mice, Knockout, Miscellaneous (drug allergy, mutagens, teratogens...), Neoplasms, Experimental - chemically induced, Neoplasms, Experimental - pathology, Penicillins - administration & dosage, Penicillins - pharmacokinetics, Penicillins - toxicity, Pharmacology. Drug treatments, Tg-rasH2 mice